Chng, Wee Joo

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia

Acute Myeloid Leukemia ResearchHistiocytic Disorders and Treatments

Cited by 4,274

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3,061

Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma

Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 983

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

Ng, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine

Cell death mechanisms and regulationLung Cancer Treatments and Mutations

Cited by 557

Enabling Technologies for Personalized and Precision Medicine

Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology

Technology and Human Factors in Education and HealthAdvanced Biosensing Techniques and Applications

Cited by 517

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 393

Telomerase directly regulates NF-κB-dependent transcription

Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., Wong, M., Zhang, Z., Li, G., Sung, W.-K., et al. (2012) · Nature Cell Biology

Telomeres, Telomerase, and SenescenceNF-κB Signaling Pathways

Cited by 378

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 351

Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

Song, T. L., Nairismägi, M.-L., Laurensia, Y., Lim, J.-Q., Tan, J., Li, Z.-M., Pang, W.-L., Kizhakeyil, A., Wijaya, G.-C., Huang, D.-C., et al. (2018) · Blood

Lymphoma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 326

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

Fonseca, R., Van Wier, S. A., Chng, W. J., Ketterling, R., Lacy, M. Q., Dispenzieri, A., Bergsagel, P. L., Rajkumar, S. V., Greipp, P. R., Litzow, M. R., et al. (2006) · Leukemia

Multiple Myeloma Research and TreatmentsLymphoma Diagnosis and Treatment

Cited by 213

HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer

Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016) · Proceedings of the National Academy of Sciences

Epigenetics and DNA MethylationCancer, Hypoxia, and Metabolism

Cited by 87

Super-enhancers and broad H3K4me3 domains form complex gene regulatory circuits involving chromatin interactions

Cao, F., Fang, Y., Tan, H. K., Goh, Y., Choy, J. Y. H., Koh, B. T. H., Hao Tan, J., Bertin, N., Ramadass, A., Hunter, E., et al. (2017) · Scientific Reports

Genomics and Chromatin DynamicsChromatin Remodeling and Cancer

Cited by 80

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification

Teoh, P. J., Chung, T.-H., Chng, P. Y. Z., Toh, S. H. M., & Chng, W. J. (2020) · Haematologica

Multiple Myeloma Research and TreatmentsCytokine Signaling Pathways and Interactions

Cited by 60

Targeting NF-κB Signaling for Multiple Myeloma

Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 42

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma

Zhou, J., & Chng, W.-J. (2022) · Cells

Multiple Myeloma Research and TreatmentsCytokine Signaling Pathways and Interactions

Cited by 22

Aberrant non-canonical NF-κB signalling reprograms the epigenome landscape to drive oncogenic transcriptomes in multiple myeloma

Ang, D. A., Carter, J.-M., Deka, K., Tan, J. H. L., Zhou, J., Chen, Q., Chng, W. J., Harmston, N., & Li, Y. (2024) · Nature Communications

Multiple Myeloma Research and TreatmentsNF-κB Signaling Pathways

Cited by 13